All In Biotech

NDA 021537 · Sandoz

Ciprodex

Ciprofloxacin, Dexamethasone · Otic · Corticosteroid

Last checked: Nov 20, 2026Latest source record: May 27, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Jul 18, 2003

Approved uses

1

Original approval plus efficacy supplements

Registered trials

364

90 Phase 3, 32 recruiting

FAERS reports

77

33 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 31, 2025.

Ciprofloxacin and dexamethasone otic suspension is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: • Acute Otitis Media (AOM) in pediatric patients (age 6 months and older) with tympanostomy tubes due to Staphylococcus aureus , Streptococcus pneumoniae , Haemophilus influenzae , Moraxella catarrhalis , and Pseudomonas aeruginosa . • Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult and elderly patients due to Staphylococcus aureus and Pseudomonas aeruginosa . Ciprofloxacin and dexamethasone otic suspension is a combination of ciprofloxacin, a fluoroquinolone antibacterial and dexamethasone, a corticosteroid, indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: • Acute Otitis Media (AOM) in pediatric patients (age 6 months and older) with tympanostomy tubes due to Staphylococcus aureus , Streptococcus pneumoniae , Haemophilus influenzae , Moraxella catarrhalis , and Pseudomonas aeruginosa . ( 1 ) • Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult, and elderly patients due to Staphylococcus aureus and Pseudomonas aeruginosa . ( 1)

Mechanism: Ciprofloxacin is a fluoroquinolone antibacterial [see Microbiology (12.4)]. Dexamethasone, a corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage, and migration of inflammatory cells.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 18, 2003 Original approval · Type 3 - New Dosage Form ReviewLetter
1 products under this application
  • CIPRODEX · CIPROFLOXACIN 0.3%; DEXAMETHASONE 0.1% · SUSPENSION/DROPS, OTIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ciprofloxacin" as an intervention, any sponsor and status, largest first.

All 364 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective11
  • fatigue7
  • product dose omission issue7
  • dizziness5
  • dyspnoea5
  • headache5
  • inappropriate schedule of product administration4
  • nausea4
  • neck pain4
  • paraesthesia4
  • pneumonia4
  • product quality issue4

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20141
20202
20215
20228
202311
202411
202531
20268

Recalls

1 FDA enforcement reports for this application.

  • Aug 13, 2025 · Class II · Ongoing

    Temperature Abuse

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ciprodex (Ciprofloxacin HCl/Dexameth)

2024 spending

$62K

Beneficiaries

264

279 claims

Per beneficiary

$235

$29.60 per unit

View as table
YearSpending
2020$12,386
2021$4,330,478
2022$6,159,648
2023$6,108,769
2024$61,934

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,835 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.